CL2020001218A1 - Compuestos útiles para inhibir a cdk7. - Google Patents

Compuestos útiles para inhibir a cdk7.

Info

Publication number
CL2020001218A1
CL2020001218A1 CL2020001218A CL2020001218A CL2020001218A1 CL 2020001218 A1 CL2020001218 A1 CL 2020001218A1 CL 2020001218 A CL2020001218 A CL 2020001218A CL 2020001218 A CL2020001218 A CL 2020001218A CL 2020001218 A1 CL2020001218 A1 CL 2020001218A1
Authority
CL
Chile
Prior art keywords
useful compounds
cdk7
inhibit cdk7
inhibit
same
Prior art date
Application number
CL2020001218A
Other languages
English (en)
Inventor
David Andrew Coates
David Michael Remick
Carlos Montero
Bharvin Kumar Rameschandra Patel
Vipin Yadav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2020001218A1 publication Critical patent/CL2020001218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVOS INHIBIDORES DE CDK7 Y COMPOSICIONES FARMACÉUTICAS DE LOS MISMOS; O UNA SAL DEL MISMO FARMACÉUTICAMENTE ACEPTABLE.
CL2020001218A 2017-11-16 2020-05-07 Compuestos útiles para inhibir a cdk7. CL2020001218A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382778 2017-11-16
EP18382034 2018-01-23
EP18382546 2018-07-20

Publications (1)

Publication Number Publication Date
CL2020001218A1 true CL2020001218A1 (es) 2020-08-21

Family

ID=64477309

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001218A CL2020001218A1 (es) 2017-11-16 2020-05-07 Compuestos útiles para inhibir a cdk7.

Country Status (31)

Country Link
US (3) US10472370B2 (es)
EP (1) EP3710446B1 (es)
JP (1) JP6633254B2 (es)
KR (1) KR102450727B1 (es)
CN (1) CN111344292B (es)
AU (1) AU2018369508B2 (es)
BR (1) BR112020008253A2 (es)
CA (1) CA3080910C (es)
CL (1) CL2020001218A1 (es)
CR (1) CR20200184A (es)
DK (1) DK3710446T3 (es)
DO (1) DOP2020000102A (es)
EC (1) ECSP20025899A (es)
ES (1) ES2925219T3 (es)
HR (1) HRP20221152T1 (es)
HU (1) HUE060078T2 (es)
IL (1) IL274540B (es)
JO (1) JOP20200122B1 (es)
LT (1) LT3710446T (es)
MD (1) MD3710446T2 (es)
MX (1) MX2020004932A (es)
MY (1) MY197700A (es)
NZ (1) NZ763551A (es)
PE (1) PE20210392A1 (es)
PL (1) PL3710446T3 (es)
RS (1) RS63530B1 (es)
SA (1) SA520411990B1 (es)
SG (1) SG11202003677UA (es)
SI (1) SI3710446T1 (es)
TW (1) TWI703149B (es)
WO (1) WO2019099298A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805218A1 (en) * 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
JP2023501950A (ja) * 2019-10-29 2023-01-20 サイロス ファーマシューティカルズ， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法
JP2023507028A (ja) 2019-12-20 2023-02-20 エボポイント、バイオサイエンシズ、カンパニー、リミテッド 複素環式化合物とその医薬組成物、調製方法、中間体及び使用
WO2022033552A1 (zh) * 2020-08-12 2022-02-17 隆泰申医药科技(南京) 有限公司 Cdk激酶抑制剂、其制备方法、药物组合物和应用
USD1004118S1 (en) 2021-08-31 2023-11-07 MerchSource, LLC Percussion massager
USD1004117S1 (en) 2021-08-31 2023-11-07 MerchSource, LLC Percussion massager
USD1004119S1 (en) 2021-08-31 2023-11-07 MerchSource, LLC Percussion massager
USD987844S1 (en) 2021-08-31 2023-05-30 MerchSource, LLC Percussion massager
USD994898S1 (en) 2021-11-17 2023-08-08 MerchSource, LLC Percussion massager
USD995812S1 (en) 2021-11-22 2023-08-15 MerchSource, LLC Percussion massager
USD1009292S1 (en) 2021-12-22 2023-12-26 MerchSource, LLC Percussion massager
USD1018881S1 (en) 2021-12-22 2024-03-19 MerchSource, LLC Percussion massager
USD1004121S1 (en) 2021-12-31 2023-11-07 MerchSource, LLC Pivoting percussion massager
USD1004122S1 (en) 2021-12-31 2023-11-07 MerchSource, LLC Pivoting percussion massager
CN114452391B (zh) * 2022-01-28 2023-08-25 深圳市泰尔康生物医药科技有限公司 Cdk16作为靶标在制备用于治疗三阴性乳腺癌的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60313872T2 (de) * 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3805218A1 (en) * 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3268000B1 (en) * 2015-03-09 2021-08-04 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
KR20180041112A (ko) 2015-06-04 2018-04-23 오리진 디스커버리 테크놀로지스 리미티드 Cdk 억제제로서의 치환된 헤테로사이클릴 유도체
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物

Also Published As

Publication number Publication date
CN111344292A (zh) 2020-06-26
KR20200070323A (ko) 2020-06-17
PE20210392A1 (es) 2021-03-02
MX2020004932A (es) 2020-08-27
LT3710446T (lt) 2022-09-26
JOP20200122A1 (ar) 2020-05-20
MY197700A (en) 2023-07-06
PL3710446T3 (pl) 2022-10-10
ES2925219T3 (es) 2022-10-14
EP3710446A1 (en) 2020-09-23
MD3710446T2 (ro) 2022-12-31
CA3080910C (en) 2023-02-07
ECSP20025899A (es) 2020-06-30
RS63530B1 (sr) 2022-09-30
CA3080910A1 (en) 2019-05-23
JOP20200122B1 (ar) 2023-09-17
AU2018369508A1 (en) 2020-05-07
TWI703149B (zh) 2020-09-01
DOP2020000102A (es) 2020-08-31
US20200017513A1 (en) 2020-01-16
US10787460B2 (en) 2020-09-29
JP2019537616A (ja) 2019-12-26
CR20200184A (es) 2020-06-01
HUE060078T2 (hu) 2023-01-28
AU2018369508B2 (en) 2021-03-11
IL274540A (en) 2020-06-30
KR102450727B1 (ko) 2022-10-06
JP6633254B2 (ja) 2020-01-22
US20190144456A1 (en) 2019-05-16
SA520411990B1 (ar) 2022-07-24
WO2019099298A1 (en) 2019-05-23
US20210032257A1 (en) 2021-02-04
NZ763551A (en) 2021-12-24
US10472370B2 (en) 2019-11-12
IL274540B (en) 2022-06-01
EP3710446B1 (en) 2022-07-20
SI3710446T1 (sl) 2022-09-30
DK3710446T3 (da) 2022-08-01
HRP20221152T1 (hr) 2022-11-25
SG11202003677UA (en) 2020-05-28
CN111344292B (zh) 2022-06-03
TW201930305A (zh) 2019-08-01
BR112020008253A2 (pt) 2020-11-17

Similar Documents

Publication Publication Date Title
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
SV2018005778A (es) Derivados aromaticos de sulfonamida
CL2017002090A1 (es) Inhibidores selectivos de bace1
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY36121A (es) ?pirazolopiridinas y pirazolopirimidinas?.
CR20160538A (es) Combinación
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
SV2016005313A (es) Derivados de carboxamida
CL2017001209A1 (es) Inhibidor de cinasa aurora a
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
UY36123A (es) Derivados de carboxamida
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2019000487A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana.
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
AR105400A1 (es) Inhibidores de jak1